Revolade variation filed with EMA for Severe Aplastic Anaemia-GSK
Glaxo Smith Kline has announced the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorisation for Revolade (eltrombopag), seeking an additional indication for the treatment of adult patients with severe Aplastic Anaemia who have had an insufficient response to immunosuppressive therapy. The EMA submission is based on the results of a pivotal open-label Phase II study (ELT112523) and two supporting Phase II studies (ELT116826 and ELT116643) by the National Institute of Health evaluating eltrombopag in patients with SAA.
In August 2014, the drug - marketed as Promacta - was approved by the FDA for once-daily use in patients with SAA who have had an insufficient response to IST.
Related news and insights
Innovent Biologics, Inc. and Eli Lilly and Company announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for Tyvyt (sintilimab injection) in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
Seagen Inc. announced full results from the pivotal phase II MOUNTAINEER trial , which showed Tukysa (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC).
Basilea Pharmaceutica Ltd., announced that its license partner, Pfizer Inc., has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the intravenous formulation of Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. This is the second approved formulation for Cresemba in China, in addition to the oral formulation for invasive aspergillosis and invasive mucormycosis.